Compare Sana Biotechnology Inc (SANA) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Health Care Select Sector SPDR Fund — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Health Care Select Sector SPDR Fund trades at $168.92. The key difference: Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | XLV | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | — |
52-Week High | $5.92 | $168.44 |
52-Week Low | $2.68 | $131.16 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
XLV, the Health Care Select Sector SPDR ETF, trades at $168.44 with a neutral daily change. Technical indicators show a bullish trend from moving averages but oscillators are neutral, with the 6-day RSI at 86.78 suggesting overbought conditions. The fund's low 0.08% expense ratio and defensive healthcare sector exposure attract steady inflows amid market volatility, as highlighted by recent ETF flow reports.
The outlook for XLV is cautiously optimistic, supported by defensive demand and strong sector earnings. Key opportunities include diversification benefits and cost efficiency, while risks involve sector-specific regulatory pressures and broader economic sensitivity. Investors should weigh the ETF's stability against potential growth limitations in a concentrated portfolio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
